NASDAQ:BSTC - BioSpecifics Technologies Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$47.00 +0.40 (+0.86 %)
(As of 07/19/2018 03:07 PM ET)
Previous Close$46.99
Today's Range$46.99 - $47.00
52-Week Range$38.05 - $53.77
Volume2 shs
Average Volume34,626 shs
Market Capitalization$339.59 million
P/E Ratio27.76
Dividend YieldN/A
Beta1.46
BioSpecifics Technologies logoBioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brand names. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

Receive BSTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BSTC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:BSTC
CUSIP09093110
Phone516-593-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio18.34
Quick Ratio18.34

Price-To-Earnings

Trailing P/E Ratio27.76
Forward P/E Ratio22.49
P/E GrowthN/A

Sales & Book Value

Annual Sales$27.44 million
Price / Sales12.33
Cash Flow$2.0311 per share
Price / Cash23.14
Book Value$9.39 per share
Price / Book5.01

Profitability

EPS (Most Recent Fiscal Year)$1.70
Net Income$11.32 million
Net Margins44.57%
Return on Equity18.92%
Return on Assets17.19%

Miscellaneous

Employees5
Outstanding Shares7,200,000
Market Cap$339.59

The Truth About Cryptocurrencies

BioSpecifics Technologies (NASDAQ:BSTC) Frequently Asked Questions

What is BioSpecifics Technologies' stock symbol?

BioSpecifics Technologies trades on the NASDAQ under the ticker symbol "BSTC."

How were BioSpecifics Technologies' earnings last quarter?

BioSpecifics Technologies Corp. (NASDAQ:BSTC) posted its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported $0.54 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.59 by $0.05. The biopharmaceutical company earned $7.09 million during the quarter, compared to analysts' expectations of $7.97 million. BioSpecifics Technologies had a return on equity of 18.92% and a net margin of 44.57%. View BioSpecifics Technologies' Earnings History.

When is BioSpecifics Technologies' next earnings date?

BioSpecifics Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for BioSpecifics Technologies.

What price target have analysts set for BSTC?

1 brokers have issued 12 month price targets for BioSpecifics Technologies' shares. Their forecasts range from $65.00 to $65.00. On average, they anticipate BioSpecifics Technologies' stock price to reach $65.00 in the next twelve months. This suggests a possible upside of 37.7% from the stock's current price. View Analyst Ratings for BioSpecifics Technologies.

What is the consensus analysts' recommendation for BioSpecifics Technologies?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioSpecifics Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about BioSpecifics Technologies stock?

Here are some recent quotes from research analysts about BioSpecifics Technologies stock:
  • 1. According to Zacks Investment Research, "BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (FDA) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for potential use as pharmaceuticals. " (7/10/2018)
  • 2. HC Wainwright analysts commented, "Wegman, issued a letter to stakeholders of the company. Mr. Wegman has been diagnosed with glioblastoma and is undergoing treatment. However, based on our conversation with Mr. Wegman, we believe he is feeling good and optimistic about the therapy. There is limited impact on his work schedule and no disruption in the company’s ongoing operations. We note that Endo International (ENDP; not rated) continues to market Xiaflex (collagenase clostridium histolyticum, or CCH) for the treatment of Peyronie’s disease and Dupuytren’s contracture, and is slated to report top-line data from the Phase 3 trial of CCH for the treatment of cellulite in 1Q19. The cellulite pivotal data readout could be the next major catalyst for BioSpecifics, in our view. In the wake of this update, we reiterate our Buy rating and $65 price target. Phase 3 cellulite data in 1Q19." (7/5/2018)

Who are some of BioSpecifics Technologies' key competitors?

Who are BioSpecifics Technologies' key executives?

BioSpecifics Technologies' management team includes the folowing people:
  • Mr. Thomas L. Wegman, CEO, Pres, Principal Financial Officer, Principal Accounting Officer, Sec. & Director (Age 63)

Has BioSpecifics Technologies been receiving favorable news coverage?

News coverage about BSTC stock has been trending somewhat positive recently, according to Accern. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioSpecifics Technologies earned a media sentiment score of 0.02 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 45.16 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of BioSpecifics Technologies?

Shares of BSTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioSpecifics Technologies' stock price today?

One share of BSTC stock can currently be purchased for approximately $47.1950.

How big of a company is BioSpecifics Technologies?

BioSpecifics Technologies has a market capitalization of $339.59 million and generates $27.44 million in revenue each year. The biopharmaceutical company earns $11.32 million in net income (profit) each year or $1.70 on an earnings per share basis. BioSpecifics Technologies employs 5 workers across the globe.

How can I contact BioSpecifics Technologies?

BioSpecifics Technologies' mailing address is 35 Wilbur Street, Lynbrook NY, 11563. The biopharmaceutical company can be reached via phone at 516-593-7000 or via email at [email protected]


MarketBeat Community Rating for BioSpecifics Technologies (NASDAQ BSTC)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  247
MarketBeat's community ratings are surveys of what our community members think about BioSpecifics Technologies and other stocks. Vote "Outperform" if you believe BSTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.